XNAS · Diagnostics & Research
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$311.98-2.62%
Model Target
—
not published for this name
Implied upside
—
vs the model target
Valuation methods
—
no method met the standard
TickerWhale Score
43/100
Weak
Score components
TickerWhale View
Natera scores 43 out of 100 overall, which we rate weak. Sentiment Signal is its strongest area and Valuation its weakest.
What helps
- Quality & growth
- Risk
- Sentiment Signal
What to watch
- Technical
- Valuation
Quality & growth
30%67Positive
- Revenue growth 37.8%
- EPS growth n/a
Valuation
25%5Weak
- P/E -232.3
- EV/Sales 16.1
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
#267 by market cap in our coverage · ~6,140 employees · Listed 2015-07-02 · www.natera.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#114 / 139sector rank by TickerWhale Score
TickerWhale Score 43 vs sector average 54.6 (-11.6)
Revenue growth (industry)Top 16%
Gross margin (industry)Top 12%
Return on equity (industry)Top 94%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
37/100Weak vs universe
Ranks 37th of 100 covered names on our technical composite — the composite itself scores 47/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 5 sell · 1 neutral of 8 votes
TickerWhale rates NTRA's technical setup weak — 37th percentile of the covered universe. Classic chart indicators lean sell, pointing the same way.
Moving averages
2 / 9constructive
- vs 200-day+15.5%
- vs 50-day-17.9%
Momentum
Mixed
- RSI (14)31 · neutral
- Stochasticbuy
- CCIsell
- Williams %Rbuy
Trend
Weak
- ADX (14) trend strength24· trending
- MACD (12,26,9)sell(histogram -12.869)
How the classic verdict is reached
Moving averages (9) agree on sell — 2 buy vs 7 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 4 sell · 1 neutral.
Result — 2 buy vs 5 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)-232.3 · TTM loss
- P/S (TTM)16.5
- P/B24.5
- EV/EBITDA—
- EV/Sales16.1
- PEG—
Profitability & returns
- Gross margin65.2%
- Net margin-7.1%
- ROE-10.7%
- Debt/Equity0.04
Growth
- Revenue growth (YoY)37.8%
- EPS growth (YoY)—
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $44.7B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target — Under Review
Our valuation methods do not currently agree closely enough for us to publish a single target for this company. We would rather say so than print a number we cannot stand behind. The TickerWhale Score still reflects quality, growth and momentum.
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NTRACurrentNatera | 43 | 47 | -232.3 | — | 24.5 | 16.1 | $311.98 | -2.62% | +37.8% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.